Press ReleaseView printer-friendly version
Materialise Reports Fourth Quarter 2016 Results
Highlights – Fourth Quarter 2016
- Total revenue increased 12.3% from the fourth quarter of 2015 to 31,477 kEUR, with increases in all three business segments.
- Total deferred revenue from annual software sales and maintenance contracts increased 3,663 kEUR from 13,136 kEUR for the fourth quarter of 2015 to 16,799 kEUR.
- Adjusted EBITDA increased 50% from 2,979 kEUR for the fourth quarter of 2015 to 4,455 kEUR.
- Net profit was 620 kEUR, or
0.01 EURper diluted share.
Fourth Quarter 2016 Results
Total revenue for the fourth quarter of 2016 increased 12.3% to 31,477 kEUR compared to 28,032 kEUR for the fourth quarter of 2015, with gains in all three of our segments, particularly Materialise Manufacturing. Adjusted EBITDA increased to 4,455 kEUR from 2,979 kEUR as a result of the combination of continued revenue growth (12.3%) and a significantly lower increase in operational expenses (3.6%) as compared to the same period in the prior year. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) in the fourth quarter was 14.2% compared to 10.6% in the fourth quarter of last year.
Revenue from our Materialise Software segment, which offers a proprietary software backbone that enables and enhances the functionality of 3D printers and 3D printing operations worldwide, increased 10.6% to 8,078 kEUR for the fourth quarter of 2016 from 7,301 kEUR for the same quarter last year. Recurrent sales from annual and renewed licenses and maintenance fees grew 37.7% from the same period in the prior year. Segment EBITDA rose to 2,949 kEUR from 2,706 kEUR while the segment EBITDA margin was 36.5% compared to 37.1% in the prior-year period.
Revenue from our Materialise Medical segment, which offers a unique platform consisting of medical planning and design software, clinical engineering services and patient specific devices, increased 5.1% to 10,061 kEUR for the fourth quarter of 2016 compared to 9,570 kEUR for the same period in 2015. Compared to the same quarter in 2015, sales of our medical software grew 29.8%, and direct sales of complex surgery solutions grew 82.9%. Segment EBITDA was 656 kEUR compared to 747 kEUR while the segment EBITDA margin decreased to 6.5% from 7.8% in the fourth quarter of 2015.
Revenue from our Materialise Manufacturing segment, which offers an integrated suite of 3D printing and engineering services to industrial and commercial customers, increased 19.4% to 13,326 kEUR for the fourth quarter of 2016 from 11,161 kEUR for the fourth quarter of 2015. End part manufacturing sales increased 26.4% compared to the last quarter in 2015. Segment EBITDA rose to 1,438 kEUR from 1,033 kEUR while the segment EBITDA margin increased to 10.8% from 9.3% for the 2015 quarter. These numbers include the results of i.materialise and RapidFit, whose activities were fully integrated into the Materialise Manufacturing business lines during the fourth quarter in order to create additional synergies.
Gross profit was 18,619 kEUR, or 59.2% of total revenue, for the fourth quarter of 2016 compared to 16,576 kEUR, or 59.1% of total revenue, for the fourth quarter of 2015.
Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 3.6% to 18,483 kEUR for the fourth quarter of 2016 from 17,849 kEUR for the fourth quarter of 2015. R&D expenses decreased from 4,742 kEUR to 4,161 kEUR while S&M expenses increased slightly from 9,340 kEUR to 9,506 kEUR. G&A expenses increased from 3,767 kEUR to 4,816 kEUR. As in the first three quarters of 2016, these changes compared to last year primarily reflected the managerial structure and support we have implemented within our S&M and R&D groups to support their significant growth since our initial public offering (“IPO”). A number of employees with mixed roles within these groups have evolved into more managerial/administrative roles, and their cost as well as certain other expenses are now categorized into G&A.
Net other operating income decreased by 426 kEUR to 1,779 kEUR compared to 2,205 kEUR for the fourth quarter of 2015. Net other operating income consists primarily of withholding tax exemptions for qualifying researchers, development grants, partial funding of R&D projects and currency exchange results on purchase and sales transactions.
Operating profit increased to 1,915 kEUR from 932 kEUR for the prior-year period. This improvement is the result of a combination of a 12.3% revenue increase and an increase of only 3.6% in operational expenses of R&D, S&M and G&A, partly offset by a 426 kEUR decrease of net other operating income compared to the same quarter last year.
Net financial result was 253 kEUR compared to 356 kEUR for the prior-year period, reflecting smaller variances in the currency exchange rates, primarily on the portion of the company’s IPO proceeds held in U.S. dollars versus the euro.
Net profit for the fourth quarter of 2016 was 620 kEUR compared to net profit of 2,145 kEUR for the same period in the prior year. The prior-year period contained income tax income of 1,010 kEUR primarily from deferred taxes compared to an expense of 898 kEUR this quarter. The variance of 1,908 kEUR in income tax and a 497 kEUR increase in the share in the loss of a joint venture offset the increase of 983 kEUR in operating profit. Total comprehensive income for the fourth quarter of 2016, which includes exchange differences on translation of foreign operations, was 685 kEUR compared to 2,010 kEUR for the same period in the prior year.
Net shareholders’ equity at
Full Year 2016 Results
Total revenues for the year ended
Revenues from our Materialise Software segment increased 16.8% to 30,122 kEUR for the year ended
Revenues from our Materialise Medical segment grew by 8.8% for the year ended
Revenues from our Materialise Manufacturing segment increased 12.1% to 46,406 kEUR for the year ended
Net loss increased from (2,860) kEUR for 2015 to a net loss of (3,019) kEUR for 2016.
Mr. Leys concluded, “The additive manufacturing market continues to evolve, particularly in the direction of end part production, and we intend to continue positioning Materialise to benefit from this promising growth market in the coming years. Our strategic priorities for 2017 are to sustain our leadership position in software through continued innovation and strategic partnerships; to drive the next stage of growth in our medical division through our focus on the hospital market; to continue increasing our manufacturing of end parts; and to enable the development of additive manufacturing in specific vertical markets. We anticipate delivering sales and Adjusted EBITDA margin expansion in 2017 while reinvesting efficiency gains in selected business development initiatives.
“For fiscal 2017, we expect to report consolidated revenue between 128,000 - 134,000 kEUR and Adjusted EBITDA between 10,500 - 13,500 kEUR. As the seasonality of our Materialise Manufacturing segment and our software businesses are expected to combine with the effects of the ramp up of the partnerships we entered into in the past months, we expect our financial results to be particularly strong in the third quarter and even stronger in the fourth quarter. We expect the amount of deferred revenue that Materialise generates from annual licenses and maintenance in 2017 to increase by an amount between 4,000 - 5,000 kEUR.”
Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding non-cash stock-based compensation expenses to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the company's day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company's business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company's ability to grow or as a valuation measurement. The company's calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company's presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.
This press release contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this press release were made at a rate of
Conference Call and Webcast
Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the fourth quarter of 2016 today,
To access the conference call, please dial 844-469-2530 (U.S.) or 765-507-2679 (international), passcode #55886457. The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com.
A replay of the conference call will be available via telephone beginning approximately one hour after the call ends through
Materialise incorporates more than 25 years of 3D printing experience into a range of software solutions and 3D printing services, which Materialise seeks to form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, current estimates of fiscal 2017 revenues, deferred revenue from annual licenses and maintenance and Adjusted EBITDA, results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies, and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from our expectations, including risk factors described in the company's annual report on Form 20-F filed with the
The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
|Consolidated income statements (Unaudited)|
|For the twelve month|
|For the three months ended||period ended 31|
|(in thousands, except EPS)||2016||2016||2015||2016||2015|
|Cost of sales||(13,554||)||(12,858||)||(11,456||)||(46,706||)||(42,963||)|
|Research and development expenses||(4,386||)||(4,161||)||(4,742||)||(17,682||)||(18,186||)|
|Sales and marketing expenses||(10,020||)||(9,506||)||(9,340||)||(36,153||)||(36,832||)|
|General and administrative expenses||(5,077||)||(4,816||)||(3,767||)||(20,041||)||(15,045||)|
|Other operating income||1,875||1,779||2,205||6,212||7,102|
|Other operating expenses||-||-||-||-||
|Share in loss of joint venture||(685||)||(650||)||(153||)||(1,018||)||(401||)|
|Profit (loss) before taxes||1,599||1,518||1,135||(1,309||)||(3,249||)|
|Net profit (loss)||652||620||2,145||(3,019||)||(2,860||)|
|Net profit (loss) attributable to:|
|The owners of the parent||652||620||2,145||(3,019||)||(2,807||)|
|Earnings per share attributable to|
|ordinary owners of the parent|
|Weighted average basic||
|Weighted average with effect dilution||47,325||47,325||47,779||47,325||47,224|
|Consolidated statements of comprehensive income (Unaudited)|
|(in thousands, except EPS)|
|For the twelve month|
|For the three months ended||period ended 31|
|Net profit (loss) for the period||652||620||2,145||(3,019||)||(2,860||)|
|Other comprehensive income (loss)|
|Exchange differences on translation of foreign operations||69||65||(135||)||(1,834||)||624|
Other comprehensive income (loss), net of taxes
|Total comprehensive income (loss) for the period, net of taxes||721||685||2,010||(4,853||)||(2,236||)|
|Total comprehensive income (loss) attributable to:|
|The owners of the parent||721||685||2,010||(4,853||)||(2,183||)|
|Consolidated statements of financial position (Unaudited)|
|31 December||31 December|
(in thousand euros)
|Property, plant & equipment||45,063||38,400|
|Investments in joint ventures||-||1,018|
|Deferred tax assets||336||1,092|
|Other financial assets||388||356|
|Total non-current assets||64,412||60,187|
|Held to maturity investments||-||-|
|Other current assets||6,247||4,993|
|Cash and cash equivalents||55,912||50,726|
|Total current assets||97,508||83,949|
Equity and liabilities
|Other comprehensive income||(1,112||)||721|
|Equity attributable to the owners of the parent||79,033||82,955|
|Loans & borrowings||28,267||16,607|
|Deferred tax liabilities||1,325||2,068|
|Other non-current liabilities||1,873||2,244|
Total non-current liabilities
|Loans & borrowings||5,539||4,482|
|Other current liabilities||10,147||9,212|
|Total current liabilities||47,834||38,357|
Total equity and liabilities
(*) Through September, 30 2016,
|Consolidated cash flow statements (Unaudited)|
|For the twelve month period|
|(in thousand euros)||31 December|
|Net profit for the period||-3,019||-2,860|
|Non-cash and operational adjustments|
|Depreciation of property, plant & equipment||6,420||5,122|
|Amortization of intangible assets||1,954||1,585|
Impairment of goodwill
|Share-based payment expense||977||769|
|Loss (gain) on disposal of property, plant & equipment||-149||-62|
|Movement in provisions||18||-116|
|Movement in allowance for bad debt||77||254|
|Impact of foreign currencies||-400||-1,530|
|Share of loss of an associate or joint venture (equity method)||1,018||401|
|Deferred tax expense (income)||374||-761|
|Fair value adjustment contingent consideration||-455||-|
|Working capital adjustments|
|Increase in trade receivables and other receivables||-6,465||-6,645|
|Decrease (Increase) in inventories||-2,482||-1,671|
|Increase in trade payables and other payables||9,086||7,148|
|Income tax paid||-530||-246|
|Net cash flow from operating activities||8,495||2,353|
|Purchase of property, plant & equipment||-12,824||-8,907|
|Purchase of intangible assets||-1,755||-1,641|
|Proceeds from the sale of property, plant & equipment, net||1,928||338|
|Acquisition of subsidiary||-||-1,619|
Investments in joint ventures
|Proceeds from held to maturity investments||-||10,000|
|Net cash flow used in investing activities||-12,640||-2,794|
|Proceeds from loans & borrowings and convertible debt||14,669||5,672|
|Repayment of loans & borrowings||-2,796||-4,711|
|Repayment of finance leases||-1,898||-1,546|
|Proceeds from the exercise of warrants||-||95|
|Purchase of non-controlling interest||-||-1,377|
|Capital increase in parent company||-||580|
|Other financial income / (expense)||-79||88|
|Net cash flow from financing activities||9,266||-1,788|
|Net increase of cash and cash equivalents||5,121||-2,229|
|Cash and cash equivalents at beginning of period||50,726||51,019|
|Exchange rate differences on cash & cash equivalents||65||1,936|
|Cash & cash equivalents at end of period||55,912||50,726|
|Reconciliation of Net Profit/(Loss) to EBITDA and Adjusted EBITDA (Unaudited)|
|For the three months||For the twelve months|
|(in thousands)||31 December||31 December|
|Net profit / (loss)||620||2,145||(3,019||)||(2,860||)|
|Share in loss of a joint venture||650||153||1018||401|
|Depreciation & amortization||2,280||1,933||8,374||6,810|
|Non-cash stock-based compensation expenses (1)||260||114||977||766|
(1) Non-cash stock-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees.
|Segment P&L (Unaudited)|
In thousands euros
|For the three month period ended 31 December 2016|
|Segment EBITDA %||36.5||%||6.5||%||10.8||%||16.0||%||13.3||%|
|For the three month period ended 31 December 2015|
|Segment EBITDA %||37.1||%||7.8||%||9.3||%||16.0||%||10.2||%|
|For the twelve month period ended 31 December 2016|
|Segment EBITDA %||33.6||%||2.4||%||8.3||%||13.0||%||7.4||%|
|For the twelve month period ended 31 December 2015|
|Segment EBITDA %||35.2||%||1.2||%||4.0||%||10.9||%||2.9||%|
Reconciliation of Net Profit/(Loss) to Segment EBITDA (Unaudited)
|(in thousands of euros)||For the three months ended December 31||For the twelve months ended December 31|
|Share in loss of joint venture||650||153||1,018||401|
|Depreciation & amortization||2,280||1,933||8,374||6,810|
|Corporate research and development||472||784||1,673||2,955|
|Corporate headquarter costs||1,781||2,027||8,646||9,700|
|Other operating income (expense)||-1,405||-1,190||-3,928||-4,416|
Harriet Fried/Jody Burfening